Study shows Melotime demonstrates prolonged melatonin release and extended half-life compared to the immediate-release formulation
MUMBAI, India, Jan. 7, 2025 /PRNewswire-PRWeb/ -- Nutriventia, a pioneer in consumer-centric nutraceutical innovations, has announced the results of a new pharmacokinetic study evaluating its novel Melotime™ sustained-release melatonin designed to support healthy sleep patterns.
According to Dr. Shefali Thanawala, Head of Medical Science and Research, the study demonstrates the unique benefits of Nutriventia's advanced delivery technology, which addresses common limitations of traditional melatonin supplements.
The study compared the pharmacokinetics of Melotime, a 5 mg sustained-release melatonin capsule to a standard 5 mg immediate-release formulation.
Study Highlights:
- Optimized Peak Concentration (Cmax): Melotime reported higher plasma concentration in the delayed phase from 4 to 8 hours as compared to immediate-release melatonin.
- Extended Half-Life: The half-life of Melotime was extended to 5.10 hours, compared to just 1.01 hours for immediate-release melatonin.
- Sustained Plasma Concentration: Melotime's innovative formulation ensures prolonged melatonin levels in the bloodstream, potentially reducing the need for frequent dosing.
About the Study
The open-label, cross-over study involved healthy men and women aged 18-45 who received either the sustained-release or immediate-release melatonin, followed by a seven-day washout period. The study measured key pharmacokinetic parameters -- maximum concentration (Cmax), time to reach Cmax, area under the curve, and elimination half-life.
Results showed that Melotime demonstrated prolonged melatonin release and extended half-life compared to the immediate-release formulation. "Melotime's sustained-release design is beneficial for bioactives like melatonin, which traditionally require repeated doses due to their short half-life," Dr. Thanawala commented. "By maintaining melatonin levels over an extended period, Melotime™ can provide more convenient and effective support for managing sleep cycles naturally."
"Further, by avoiding sharp peaks in melatonin concentration, which are common with immediate-release formulations, the study demonstrates that Melotime's smooth, controlled release helps ensure melatonin levels remain balanced, especially during critical early morning hours, promoting safer and more consistent support for healthy sleep patterns," explained Rajat Shah, Director.
For more information, visit www.nutriventia.com.
About Nutriventia:
Nutriventia is a leading innovator in the nutraceutical industry, dedicated to developing cutting-edge delivery technologies for bioactive ingredients. With a focus on scientific research and clinical validation, Nutriventia creates high-quality, effective supplements that address modern health challenges. Our commitment to innovation and excellence has positioned us as a trusted partner for brands seeking to differentiate their products in the competitive wellness market.
Media Contact
Pamela Stewart, Nutriventia, 1 3035701678, [email protected], www.nutriventia.com
SOURCE Nutriventia
Share this article